NEOMERO-2. Pharmacokinetics and safety of Meropenem in infants below 90 days of age (inclusive) with probable and confirmed meningitis: A European Multicenter Phase I-II Trial

Trial Profile

NEOMERO-2. Pharmacokinetics and safety of Meropenem in infants below 90 days of age (inclusive) with probable and confirmed meningitis: A European Multicenter Phase I-II Trial

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Feb 2016

At a glance

  • Drugs Meropenem (Primary)
  • Indications Bacterial meningitis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms NeoMero-2
  • Most Recent Events

    • 08 Feb 2016 The trial status is given as active, no longer recruiting in UKCRN,and completed in NCT; retained as per NCT because it includes more locations than UKCRN
    • 20 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 14 Oct 2014 Accrual to date is 41% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top